Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Novo Nordisk: A long acting, selective human insulin analog, NN1213, for weight management Novo Nordisk Offers New Contender in Weight Management Novo Nordisk defends disappointing next gen obesity drug: 'It will be an important product' NBC Connecticut Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN